KalVista Pharma Q4 EPS $(0.77) Beats $(0.89) Estimate; Cash, Cash Equivalents & Marketable Securities Of $149.4M Providing Runway Into 2025
Portfolio Pulse from Benzinga Newsdesk
KalVista Pharma reported Q4 losses of $(0.77) per share, beating the analyst consensus estimate of $(0.89) by 13.48 percent. This is a 21.43 percent increase over losses of $(0.98) per share from the same period last year. The company also reported cash, cash equivalents & marketable securities of $149.4M.
July 07, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
KalVista Pharma's Q4 earnings beat analyst estimates, showing a smaller loss than expected. This could potentially boost investor confidence in the company's financial performance.
KalVista Pharma's Q4 earnings beat analyst estimates, which is generally seen as a positive sign by investors. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100